ramipril
Commercial- Indications
- Hypertension
Company intelligence / Profile preview
Prior to its acquisition by Pfizer in early March of 2011, King Pharmaceuticals was a commercial-stage specialty pharmaceutical company with a portfolio focused on pain management, cardiovascular disease, emergency medicine devices such as the EpiPen auto-injector, and animal health. Its key product Altace benefited from strong clinical data showing significant reduction in cardiovascular events. The company also developed new formulations designed to deter opioid misuse and abuse. At the time of acquisition it had several marketed products but limited late-stage R&D activity.
5 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on King Pharmaceuticals, Inc..